Trials / Completed
CompletedNCT02300701
Role of Anti-IgE in Severe Childhood Eczema
The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 4 Years – 19 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of anti-IgE (Omalizumab/Xolair) in children with severe eczema.
Detailed description
To address the value of anti-IgE in children with severe eczema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xolair | According to manufacturer's instructions |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2014-11-25
- Last updated
- 2019-08-09
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02300701. Inclusion in this directory is not an endorsement.